ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2796

A Novel Mouse Model of Osteochondromagenesis By Deleting NFATc1 in Mesenchymal Progenitors and Postnatal Chondrocytes

Xian-Peng Ge1, Susan Y. Ritter2, Julia F. Charles3, Kelly Tsang2 and Antonios O. Aliprantis2, 1Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Rheumatology, Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Animal models, bone disease, cartilage, transcription factor and tumor suppressors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint I: Bone Remodeling in Inflammation and Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Osteochondromas are the most common benign bone tumor and are characterized by cartilage-capped bony projections from the external surface of bone. These lesions may cause pain, deformity, fracture and neurovascular compromise, and rarely undergo malignant transformation. The pathogenesis of osteochondroma remains poorly understood. Since we recently reported that transcription factor nuclear factor of activated T cells c1 (NFATc1) suppresses osteoarthritis in mice, we hypothesized that it controls other aspects of chondrocyte biology. The objective of this study was to further characterize potential roles of NFATc1 in mesenchymal progenitors and chondrocytes.

Methods:

To investigate the role of NFATc1 in mesenchymal progenitors of the limb bud and in postnatal chondrocytes, Nfatc1fl/fl mice were bred to Prx1-Cre (hereafter Nfatc1Prx1) or tamoxifen-inducible Aggrecan-CreERT2 (hereafter Nfatc1Aggrecan-CreER) mice, respectively. Nfatc1Aggrecan-CreER mice were analyzed on either an NFATc2-sufficient (Nfatc2+/-) or deficient (Nfatc2-/-) background to check for redundancy among NFAT family members. Nfatc1 was deleted in Nfatc1Aggrecan-CreER chondrocytes by administration of tamoxifen at 8 weeks or 12 weeks of age. The skeletal and joint phenotypes of these strains were determined by a combination of micro-CT and histology.

Results:

Nfatc1Prx1 mice displayed ectopic cartilage and bone formation around the knee joints (osteochondromatosis) at 16 weeks of age. Similarly, within 1 month of tamoxifen injection, all Nfatc1aggrecan-creERNfatc2+/- mice displayed ectopic cartilage formation at the tibial attachment site of the medial collateral ligament. Three months after the administration of tamoxifen, Nfatc1aggrecan-creERNfatc2+/- mice showed clear osteochondroma-like exostoses at the ligament-bone attachment site, characterized histologically by cartilage-capped bony protrusions continuous with underlying bone. In some Nfatc1aggrecan-creERNfatc2+/- mice, cartilaginous protrusions outgrew from the epiphyses of knee joints at this time point. Lastly, the osteochondromagenesis previously reported around the hip joints in Nfatc2-/- mice, was exacerbated in Nfatc1aggrecan-creERNfatc2-/- double knockout mice.

Conclusion:

Our data indicate that NFATc1 constitutively represses chondrogenesis and the formation of exostoses in mice. Reducing NFATc1 expression in mesenchymal progenitors or postnatal aggrecan-expressing chondrocytes represents a novel animal model of osteochondromagenesis.


Disclosure:

X. P. Ge,
None;

S. Y. Ritter,
None;

J. F. Charles,
None;

K. Tsang,
None;

A. O. Aliprantis,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-mouse-model-of-osteochondromagenesis-by-deleting-nfatc1-in-mesenchymal-progenitors-and-postnatal-chondrocytes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology